Predictors Of 30-Day Readmission In Patients Hospitalized With Decompensated Cirrhosis in a Large State Based Inpatient Sample
AASLD LiverLearning®, Sehem Ghazala, 144642
Mental Health Predictors of All Oral Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection
AASLD LiverLearning®, Jennifer Kramer, 144643
Risk Factors Associated with Colonization or Infection with a Multi-Drug Resistant Organism in Patients with Cirrhosis
AASLD LiverLearning®, Monica Schmidt, 144644
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal dysfunction; From real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144900
Geographic Disparities in Incidence and All Cause Mortality Among Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Ricardo Franco, 144645
Real-life Hepatitis C treatment: effectiveness of 8 or 12 week Sofosbuvir/Ledipasvir in Genotype 1 non-cirrhotic treatment-naive mono or HIV-coinfected patients
Safety and Efficacy of Sofosbuvir in Combination with Daclatasvir or Simeprevir With or Without Ribavirin in the Treatment of Chronic HCV Genotype 4-infected Patients: A Real World Experience.
AASLD LiverLearning®, Ali Albenmousa, 144902
Hepatitis A and B vaccination rates in patients with chronic liver disease: A Quality Improvement Project
AASLD LiverLearning®, Moaz Sial, 144658
Eliminating Hepatitis C in Spain: Bridging from the National Health Plan
AASLD LiverLearning®, Maria Buti, 144659
Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis
AASLD LiverLearning®, David Goldberg, 144660
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network
AASLD LiverLearning®, Kevin Korenblat, 144916
Alcohol use disorder among chronic hepatitis C patients: prevalence and treatment outcome, CHeCS, 2006-2013
AASLD LiverLearning®, Eyasu Teshale, 144661
Are office visits and laboratory data monitoring required for chronic hepatitis C genotype 1 patients treated with Sofosbuvir based regimens that do not include Ribavirin?
AASLD LiverLearning®, Apurva Modi, 144917
Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience
AASLD LiverLearning®, John Koskinas, 144918
Low Rates of Hepatitis B Virus (HBV) Screening and Low Rates of HBV Awareness Among High Risk Patients at a Large, Urban, Safety-Net Hospital
AASLD LiverLearning®, Robert Wong, 144674
Increased risk of hepatocellular carcinoma in patients with low-level viremia than maintained virological remission in patients receiving entecavir monotherapy
AASLD LiverLearning®, jung hee kim, 144675
HDV RNA replication is associated with high HBsAg levels irrespective of HBV DNA and linked with severe liver damage and end-stage liver disease complications
AASLD LiverLearning®, Ivana Carey, 144676
Assessment of Presence and Dynamic evolution of Organ Failures during Early Intensive Management by MERCIC model can guide inappropriate ‘Futile Care’ in the first week in Critically Ill Cirrhotics
AASLD LiverLearning®, RAKHI MAIWALL, 144932
Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencing
AASLD LiverLearning®, XIUMEI CHI, 144677
Which Extra-hepatic Organ Fails First does not affect Mortality Rates in Cirrhotic Inpatients
AASLD LiverLearning®, Jasmohan S. Bajaj, 144933
Elevated Ferritin is Associated with Increased Mortality in Patients with Cirrhosis Admitted to Intensive Care Units
AASLD LiverLearning®, Christina Lindenmeyer, 144934
Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma - final results
AASLD LiverLearning®, Pietro Lampertico, 144690
A Primary Care and Community-Based Hepatitis B Screening and Linkage-to-Care Program in New Jersey
AASLD LiverLearning®, Su Wang, 144691
Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B
AASLD LiverLearning®, Onur Keskin, 144692
Factors predictive of infections in acute decompensated cirrhosis patients may help identify infections sooner than later: value of SIRS criteria upon admission.
AASLD LiverLearning®, Sandeep Yarlagadda, 144948
A brief introduction to the community-based comprehensive management of Hepatitis B demonstration project in Jiangsu province, china
AASLD LiverLearning®, Xiangjun Zhai, 144693
Novel Serum Biomarkers Predict Outcome in Compensated Cirrhosis
AASLD LiverLearning®, Audrey Dillon, 144949
Predicting Mortality in Patients with Cirrhosis Admitted to Intensive Care Units: A Novel Prognostic Model
AASLD LiverLearning®, Christina Lindenmeyer, 144950
Obstetricians’ Knowledge and Practices Regarding Chronic Hepatitis B in Pregnancy
AASLD LiverLearning®, Bolin Niu, 144707
Development of Hepatocellular Carcinoma after Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
AASLD LiverLearning®, Sun Hong Yoo, 144708
External Abdominal Compression for Refractory Ascites: A Pilot Study
AASLD LiverLearning®, Patrick Chen, 144964
Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in chronic hepatitis B patients: an analysis using time-dependent ROC
AASLD LiverLearning®, Toshifumi Tada, 144709
Pre-treatment and on-treatment predictors for the efficacy of tolvaptan in the treatment of refractory ascites due to cirrhosis
AASLD LiverLearning®, Yasuyuki Kommiyama, 144965
Over One Third of Chronic Hepatitis B Virus Patients Have Concurrent Nonalcoholic Fatty Liver Disease, With the Highest Risk Among Non-Asians and Patients with Metabolic Risk Factors
AASLD LiverLearning®, Wada Sharma, 144710
Targeted heart rate reduction using carvedilol± ivabradine improves left ventricular diastolic dysfunction, clinical progression and survival in cirrhosis
AASLD LiverLearning®, Madhumita Premkumar, 144966
Proportion of Pre-Core Mutation Determines HBV Phenotype after HBeAg Seroconversion
AASLD LiverLearning®, Daniel Suarez, 144723
Non-invasive prediction of liver disease in a multi-genotype cohort of hepatitis B e antigen negative patients
AASLD LiverLearning®, Gayatri Chakrabarty, 144724
Survival Benefit and Morbidity With Terlipressin Plus Albumin in Treating Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
AASLD LiverLearning®, Harsha Moole, 144980
Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir
AASLD LiverLearning®, Hiroki Nishikawa, 144725
Cirrhosis in hemodialyzed patients: time to decision is related to liver function
AASLD LiverLearning®, Florent Artru, 144981
Unexplained chronic liver disease in Eastern Ethiopia: a cross-sectional study
AASLD LiverLearning®, Stian M S Orlien, 144726
Development of a novel staging model for cirrhosis outcome using the Nationwide Inpatient Sample
AASLD LiverLearning®, Mona Haj, 144982
High Rate of HBsAg Loss After Peginterferon Based Combination Treatment for Chronic Hepatitis B Patients: Results After 5 Years of Follow-up
AASLD LiverLearning®, Femke Stelma, 144739
Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
AASLD LiverLearning®, Andrew Vaillant, 144740
Serum Creatinine for Given MELD Score Impacts Outcomes After Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Tom Catron, 144996
LUNAR™-HBV, a UNA Oligomer Combination for the Treatment of Chronic Hepatitis B Virus Infection
AASLD LiverLearning®, Christine Esau, 144741
L-Isoleucine independently regulates protein synthesis and mitochondrial respiration in skeletal muscle cells during hyperammonemia
AASLD LiverLearning®, Srinivasan Dasarathy, 144997
HBV Core Assembly Modulators Block Antigen Production when Present during Infection, but not during Persistent Infection
AASLD LiverLearning®, Angela Lam, 144742
Changes in Antimicrobial Susceptibility of Fecal Bacteria During Rifaximin Treatment for the Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144998
HBV Genotype Differences in Treatment Response to TAF and TDF
AASLD LiverLearning®, Maria Buti, 144755
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection
AASLD LiverLearning®, Xiang-Yong Li, 144756
Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection
AASLD LiverLearning®, Ammen Dhillon, 144757
Evaluation of antiviral effects of a novel site-specific pegylated interferon beta using humanized mouse model
AASLD LiverLearning®, Masataka Tsuge, 144758
Characterization of host, viral, and treatment-related factors associated with antiviral efficacy of tenofovir alafenamide (TAF) and tenofovir disporoxil (TDF)
AASLD LiverLearning®, Edward Gane, 144771
Identification of novel CD8+ T-cell epitopes in HLA-A24-positive patients with hepatitis B virus.
AASLD LiverLearning®, Kiichiro Kaji, 144772
Safety, Tolerability and Pharmacokinetics of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Healthy Subjects.
AASLD LiverLearning®, Jeysen Yogaratnam, 144773
Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
AASLD LiverLearning®, Calvin Pan, 144774
Fatigue & Hepatitis C: A Focus Group Study
AASLD LiverLearning®, Zobair Younossi, 144531
High HCV Cure Rates After Directly Acting Antivirals In Patients with Chronic Hepatitis C and Psychiatric Disorders
AASLD LiverLearning®, Anne Moore, 144532
The effect after cessation of nucleos(t)ide analog(ue)s for chronic hepatitis B virus infection patients who had serum HBsAg negative is durable
AASLD LiverLearning®, Xiang-Yong Li, 144788
Predictors of non-adherence to HBV anti-viral therapy
AASLD LiverLearning®, Suzanne Sheppard-Law, 144533
Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs)
AASLD LiverLearning®, Qi Huang, 144789
Polyethylenimines (PEI) polymer functionalized with L-mannose moieties inhibits hepatitis B virus (HBV) entry into HepG2-hNTCP cells with negligible cellular toxicity.
AASLD LiverLearning®, Guan Huei Lee, 144790
Nucleos(t)ide Analogue Discontinuation is not Associated with Increased Rates of HBsAg Loss in Chronic Hepatitis B
AASLD LiverLearning®, Heng Chi, 144791
The Role of Repeat Liver Biopsies in Autoimmune Hepatitis (AIH) at a Tertiary HPB Centre in South England, UK: Current experience, clinical dilemmas and recommendations
AASLD LiverLearning®, Claire Kelly, 144547
Autoimmune hepatitis: Impact of age at disease onset on disease severity, outcome and response to treatment.
AASLD LiverLearning®, Nikolaos Gatselis, 144548
Factors affecting clinical trial enrollment in patients with hepatitis C virus (HCV)
AASLD LiverLearning®, Vijaya L. Rao, 144804
Black and Latino Race/Ethnicity Increase the Risk of Hospitalization for Autoimmune Hepatitis in the United States
AASLD LiverLearning®, Jason Wen, 144549
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
AASLD LiverLearning®, George Ioannou, 144805
Experience with Direct Antiviral Agents in Hispanic patients with Chronic Hepatitis C genotype 1 at the Veteran Affairs Caribbean Healthcare System in San Juan
AASLD LiverLearning®, Arnaldo L Freire-Perez, 144806
The role of Thy-1 in the pathogenesis of cholestatic liver fibrosis
AASLD LiverLearning®, Yukinori Koyama, 144563
TANGO1 mediates fibrogenesis in vivo and is regulated by the UPR
AASLD LiverLearning®, Jessica Maiers, 144564
Ribavirin plasma level is an independent predictor for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination (HepNed study 002)
AASLD LiverLearning®, Faydra Lieveld, 144820
The I148M PNPLA3 variant is a novel key player modulating the pro-fibrogenic phenotype of human hepatic stellate cells
AASLD LiverLearning®, Francesca Bruschi, 144565
The efficacy and safety of sofosbuvir plus ribavirin with or without peg-interferon in treatment of naïve and experienced Vietnamese patients with chronic genotype 1 and 6 HCV infection.
AASLD LiverLearning®, Thu Thuy Pham Thi, 144821
Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort
AASLD LiverLearning®, Salvatore Madonia, 144822
Inhibition of vascular endothelial growth factor signaling facilitates recovery from acute ethanol-induced liver injury in zebrafish
AASLD LiverLearning®, Chunyue Yin, 144579
Profibrogenic properties of monoacylglycerol lipase in macrophages
AASLD LiverLearning®, Aida Habib, 144580
Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
AASLD LiverLearning®, Francesca Ceccherini-Silberstein, 144836
The Expression of MicroRNA-101 in Hepatic Cirrhosis - Hepatocellular Carcinoma and Its Effects on Hepatic Fibrosis
AASLD LiverLearning®, Chenghai Liu, 144581
Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD)
AASLD LiverLearning®, Marc Bourliere, 144837
The Impact of Hepatitis C Virus Cure on Progression of Renal Disease
AASLD LiverLearning®, Carla Rodriguez, 144838
Combination therapy with mesenchymal stem cells and macrophages from bone marrow shows favorable outcome in mouse CCl4-induced liver cirrhosis model
AASLD LiverLearning®, Yusuke Watanabe, 144595
Frequency and Profile of decompensation in cirrhotics with Hepatic Venous Pressure Gradient below 10 mm Hg: Need to redefine CSPH
AASLD LiverLearning®, Ankit Bhardwaj, 144596
Quality of life of HCV patients treated with new direct-acting antiviral agents decreases during the first week of treatment and is inversely correlated with HCV viral load: a single-center prospective study
AASLD LiverLearning®, Christophe Renou, 144852
The Usefullness of WFA+-M2BP for predicting gastroesophageal varices and liver related events in HCV-related cirrhosis.
AASLD LiverLearning®, Tsuguru Hayashi, 144597
Hepatitis C Virus treatment outcomes in an inner-city population: 2004-2015
AASLD LiverLearning®, Vijay Dalapathi, 144853
The safety, tolerability and efficacy of paritaprevir/ritonavir/ombitasvir and dasabuvir with ribavirin in a large real life multi-center cohort of genotype 1b HCV infected patients with liver cirrhosis at the edge of decompensation
AASLD LiverLearning®, Ana Maria Singeap, 144854
Cost effectiveness analysis of potentially curative treatments for hepatocellular carcinoma with person-level data in a Canadian setting
AASLD LiverLearning®, Hla-Hla (Rosie) Thein, 144611
The Economic and Clinical Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the United States and Europe: A Steady-State Prevalence Model
AASLD LiverLearning®, Zobair Younossi, 144612
Impact of HCV Therapy with Direct-Acting Antivirals on Lipid Profiles
AASLD LiverLearning®, Pooja Dharwadkar, 144868
Cost and utility estimates for patients at different stages in the natural history of Primary Biliary Cirrhosis (PBC) from the UK-PBC Cohort
AASLD LiverLearning®, Stephen Rice, 144613
Effects of interferon-free treatment on serum cholesterol levels are different between the two sofosbuvir-based regimens in chronic HCV-infected patients
AASLD LiverLearning®, Naohiko Masaki, 144869
Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world.
AASLD LiverLearning®, Dost Sarpel, 144870
Potential Conflicts of Interest for Authors of Recent AASLD Clinical Practice Guidelines
AASLD LiverLearning®, Audrey Dillon, 144627
Comprehensive Liver Cancer Center Approach to Improve Treatment-Lag in Patients with Hepatocellular Carcinoma: A Tertiary Center Experience
AASLD LiverLearning®, Ramzi Mulki, 144628
Efficacy of All-Oral HCV Therapy in People Who Inject Drugs (PWID)
AASLD LiverLearning®, Brian Conway, 144884
Trends Comparing Alcohol Related Liver Disease in Women and Men in the United States from 2006 and 2013: A Nationwide Analysis
AASLD LiverLearning®, Lauren Stemboroski, 144629
Daclatasvir (DCV) plus Sofosbuvir (SOF) regimens in chronic Hepatitis C Virus (HCV) infected patients with advanced fibrosis or cirrhosis
AASLD LiverLearning®, Ioannis S Elefsiniotis, 144885
Effectiveness and safety of direct-acting antiviral therapies (DAA) in cirrhotic HCV monoinfected and HIV/HCV coinfected patient
AASLD LiverLearning®, Pilar Carmona, 144886